GSK plc SEC EDGAR Filings (CIK 0001131399)

SEC EDGAR filings, ownership reports, and insider transactions for GSK plc.

Symbol
GSK on NYSE, GLAXF on OTC
Industry
Pharmaceutical Preparations (Office Of Life Sciences)
Business address
79 New Oxford Street, London, WC1A 1DG
Top holdings (ownership)
WVE, LYEL, SPRO, and CVRX
Top holdings (Schedule 13D)
CVAC and SPRO
State of incorporation
United Kingdom
Former names
GLAXOSMITHKLINE PLC (to 16 May 2022)
⭐ Add to watchlist ⭐
Get insider transactions for this reporting owner
GSK plc has filed 6,619 SEC EDGAR filings since 12 Jan 2001

Latest Filings

Recent SEC filings for GSK plc including SC TO-C, 6-K, 4 and more.

Form type Document Filing Description Filing date Reporting date File number(s)
SC TO-C Open SC TO-C document View SEC filing for SC TO-C SC TO-C 20 Jan 2026
SC TO-C Open SC TO-C document View SEC filing for SC TO-C SC TO-C 20 Jan 2026
6-K Open 6-K document View SEC filing for 6-K GSK TO ACQUIRE RAPT THERAPEUTICS 20 Jan 2026 20 Jan 2026 001-15170
6-K Open 6-K document View SEC filing for 6-K AGREEMENT ON CHANGES TO VIIV MINORITY SHAREHOLDING 20 Jan 2026 20 Jan 2026 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 16 Jan 2026 16 Jan 2026 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 15 Jan 2026 15 Jan 2026 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Jan 2026 13 Jan 2026 001-15170
6-K Open 6-K document View SEC filing for 6-K EC APPROVAL OF SHINGRIX PFS 07 Jan 2026 07 Jan 2026 001-15170
6-K Open 6-K document View SEC filing for 6-K POSITIVE PHASE 3 DATA FOR GSK'S BEPIROVIRSEN 07 Jan 2026 07 Jan 2026 001-15170
6-K Open 6-K document View SEC filing for 6-K EXDENSUR APPROVED IN JAPAN 06 Jan 2026 06 Jan 2026 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 05 Jan 2026 05 Jan 2026 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 05 Jan 2026 05 Jan 2026 001-15170
6-K Open 6-K document View SEC filing for 6-K NUCALA FOR ADULTS WITH COPD APPROVED IN CHINA 05 Jan 2026 05 Jan 2026 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK TO LOWER DRUG PRICES AND EXPAND ACCESS IN US 23 Dec 2025 23 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 22 Dec 2025 22 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 22 Dec 2025 22 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 19 Dec 2025 19 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 18 Dec 2025 18 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K EXDENSUR (DEPEMOKIMAB ULLA) APPROVED BY US FDA 17 Dec 2025 17 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 17 Dec 2025 17 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K EXDENSUR (DEPEMOKIMAB) UK MHRA APPROVAL 16 Dec 2025 16 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 16 Dec 2025 16 Dec 2025 001-15170
4 Open 4 document View SEC filing for 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP 15 Dec 2025 11 Dec 2025 001-37627
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 15 Dec 2025 15 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DEPEMOKIMAB RECEIVES POSITIVE CHMP OPINION 12 Dec 2025 12 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K NUCALA RECEIVES POSITIVE CHMP OPINION FOR COPD 12 Dec 2025 12 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K POSITIVE CHMP OPINION ON AREXVY FOR ALL ADULTS 18+ 12 Dec 2025 12 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 12 Dec 2025 12 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K BLUJEPA APPROVED IN US FOR GONORRHOEA INDICATION 11 Dec 2025 11 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 11 Dec 2025 11 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING APPLICATION 11 Dec 2025 11 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 11 Dec 2025 11 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 10 Dec 2025 10 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK'227 US FDA ORPHAN DRUG DESIGNATION IN SCLC 10 Dec 2025 10 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 09 Dec 2025 09 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 09 Dec 2025 09 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 08 Dec 2025 08 Dec 2025 001-15170
SCHEDULE 13D/A Open SCHEDULE 13D/A document View SEC filing for SCHEDULE 13D/A 05 Dec 2025
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 05 Dec 2025 05 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 04 Dec 2025 04 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 03 Dec 2025 03 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 02 Dec 2025 02 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 01 Dec 2025 01 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Dec 2025 01 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 01 Dec 2025 01 Dec 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 28 Nov 2025 28 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 28 Nov 2025 28 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 26 Nov 2025 26 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 25 Nov 2025 25 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 24 Nov 2025 24 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K INITIATION OF LITIGATION AGAINST ANAPTYSBIO INC 21 Nov 2025 21 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 21 Nov 2025 21 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 20 Nov 2025 20 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSFER OF TREASURY SHARES 19 Nov 2025 19 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 19 Nov 2025 19 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 18 Nov 2025 18 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 18 Nov 2025 18 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 17 Nov 2025 17 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 14 Nov 2025 14 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Nov 2025 13 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 13 Nov 2025 13 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING INTERIM REVIEW 12 Nov 2025 12 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 12 Nov 2025 12 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 12 Nov 2025 12 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK PUBLISHES PROVISIONAL DIVIDEND DATES 10 Nov 2025 10 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 10 Nov 2025 10 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 07 Nov 2025 07 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 06 Nov 2025 06 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 05 Nov 2025 05 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 04 Nov 2025 04 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 03 Nov 2025 03 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 03 Nov 2025 03 Nov 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 31 Oct 2025 31 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 30 Oct 2025 30 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 30 Oct 2025 30 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 29 Oct 2025 29 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K 3RD QUARTER RESULTS 29 Oct 2025 29 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 28 Oct 2025 28 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK ADC GETS ORPHAN DRUG DESIGNATION IN THE EU 28 Oct 2025 28 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 27 Oct 2025 27 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K BLENREP APPROVED BY US FDA IN MULTIPLE MYELOMA 24 Oct 2025 24 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 24 Oct 2025 24 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 23 Oct 2025 23 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K POSITIVE DATA FOR LOW CARBON VERSION VENTOLIN MDI 22 Oct 2025 22 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 22 Oct 2025 22 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K LATOZINEMAB DATA READ OUT 22 Oct 2025 22 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K POSITIVE CHMP OPINION FOR GSK ON SHINGRIX PFS 21 Oct 2025 21 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 21 Oct 2025 21 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK SHARE POSITIVE PH3 DATA ON TEBIPENEM HBR 21 Oct 2025 21 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 20 Oct 2025 20 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 17 Oct 2025 17 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 16 Oct 2025 16 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 16 Oct 2025 16 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 15 Oct 2025 15 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 15 Oct 2025 15 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK RECEIVES EXPANDED SHINGRIX APPROVAL IN CHINA 14 Oct 2025 14 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 14 Oct 2025 14 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 14 Oct 2025 14 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 14 Oct 2025 14 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 10 Oct 2025 10 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 10 Oct 2025 10 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 09 Oct 2025 09 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 08 Oct 2025 08 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 07 Oct 2025 07 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 06 Oct 2025 06 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 03 Oct 2025 03 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 02 Oct 2025 02 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Oct 2025 01 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 01 Oct 2025 01 Oct 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK - THIRD TRANCHE OF SHARE BUYBACK PROGRAMME 30 Sep 2025 30 Sep 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK APPOINTS CEO DESIGNATE 29 Sep 2025 29 Sep 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 22 Sep 2025 22 Sep 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 19 Sep 2025 19 Sep 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 18 Sep 2025 18 Sep 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK US INVESTMENT ANNOUNCEMENT 17 Sep 2025 17 Sep 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 17 Sep 2025 17 Sep 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 16 Sep 2025 16 Sep 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 15 Sep 2025 15 Sep 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 12 Sep 2025 12 Sep 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 11 Sep 2025 11 Sep 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 10 Sep 2025 10 Sep 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 10 Sep 2025 10 Sep 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 09 Sep 2025 09 Sep 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 08 Sep 2025 08 Sep 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 05 Sep 2025 05 Sep 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 04 Sep 2025 04 Sep 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 04 Sep 2025 04 Sep 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 03 Sep 2025 03 Sep 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 02 Sep 2025 02 Sep 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 Sep 2025 02 Sep 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 02 Sep 2025 02 Sep 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 29 Aug 2025 29 Aug 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 28 Aug 2025 28 Aug 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 27 Aug 2025 27 Aug 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 26 Aug 2025 26 Aug 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 22 Aug 2025 22 Aug 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 21 Aug 2025 21 Aug 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 21 Aug 2025 21 Aug 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 20 Aug 2025 20 Aug 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 19 Aug 2025 19 Aug 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 19 Aug 2025 19 Aug 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 18 Aug 2025 18 Aug 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 15 Aug 2025 15 Aug 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 14 Aug 2025 14 Aug 2025 001-15170
SCHEDULE 13D Open SCHEDULE 13D document View SEC filing for SCHEDULE 13D 13 Aug 2025
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 13 Aug 2025 13 Aug 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Aug 2025 12 Aug 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 12 Aug 2025 12 Aug 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K FDA TO REVIEW GONORRHEA INDICATION FOR GEPOTIDACIN 11 Aug 2025 11 Aug 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 11 Aug 2025 11 Aug 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K CUREVAC/BIONTECH MRNA PATENT LITIGATION SETTLEMENT 08 Aug 2025 08 Aug 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 08 Aug 2025 08 Aug 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 07 Aug 2025 07 Aug 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 06 Aug 2025 06 Aug 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 05 Aug 2025 05 Aug 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 04 Aug 2025 04 Aug 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Aug 2025 01 Aug 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 01 Aug 2025 01 Aug 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 31 Jul 2025 31 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K 2ND QUARTER RESULTS 30 Jul 2025 30 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 30 Jul 2025 30 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 29 Jul 2025 29 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK ENTERS HENGRUI PHARMA COLLABORATION AGREEMENTS 28 Jul 2025 28 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K PRIMARY DOCUMENT 28 Jul 2025 28 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 25 Jul 2025 25 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K BLENREP APPROVED IN THE EU FOR MULTIPLE MYELOMA 24 Jul 2025 24 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 24 Jul 2025 24 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K US FDA REVIEW EXTENDED FOR BLENREP 23 Jul 2025 23 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 23 Jul 2025 23 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 22 Jul 2025 22 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 21 Jul 2025 21 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 18 Jul 2025 18 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K BLENREP US ODAC OUTCOME 18 Jul 2025 18 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 18 Jul 2025 18 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K GSKS SHINGRIX FULLY LIQUID FDA APPROVAL 17 Jul 2025 17 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 17 Jul 2025 17 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 16 Jul 2025 16 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 15 Jul 2025 15 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 15 Jul 2025 15 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 14 Jul 2025 14 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK SUBMITS AREXVY FOR ADULTS 18-49 AIR TO FDA 14 Jul 2025 14 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 14 Jul 2025 14 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 11 Jul 2025 11 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 10 Jul 2025 10 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 09 Jul 2025 09 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 08 Jul 2025 08 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK COMPLETES ACQUISITION OF EFIMOSFERMIN FOR SLD 07 Jul 2025 07 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 07 Jul 2025 07 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 07 Jul 2025 07 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 03 Jul 2025 03 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 02 Jul 2025 02 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Jul 2025 01 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 01 Jul 2025 01 Jul 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 30 Jun 2025 30 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 27 Jun 2025 27 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 26 Jun 2025 26 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 25 Jun 2025 25 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 24 Jun 2025 24 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR DECLARATION 24 Jun 2025 24 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 24 Jun 2025 24 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 23 Jun 2025 23 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K LINERIXIBAT FILE ACCEPTED BY EMA 23 Jun 2025 23 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 23 Jun 2025 23 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K AREXVY FILED IN JAPAN FOR 18-49 AT INCREASED RISK 20 Jun 2025 20 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 20 Jun 2025 20 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 20 Jun 2025 20 Jun 2025 001-15170
11-K Open 11-K document View SEC filing for 11-K ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE 18 Jun 2025 31 Dec 2024 001-15170
11-K Open 11-K document View SEC filing for 11-K ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE PLANS 18 Jun 2025 31 Dec 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 18 Jun 2025 18 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 17 Jun 2025 17 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 16 Jun 2025 16 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Jun 2025 13 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 13 Jun 2025 13 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK SUBMITS AREXVY FOR ADULTS 18+ WITH EMA 13 Jun 2025 13 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Jun 2025 12 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 12 Jun 2025 12 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 11 Jun 2025 11 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 11 Jun 2025 11 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 10 Jun 2025 10 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 09 Jun 2025 09 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 06 Jun 2025 06 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 05 Jun 2025 05 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK - SECOND TRANCHE OF SHARE BUYBACK PROGRAMME 04 Jun 2025 04 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 04 Jun 2025 04 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 03 Jun 2025 03 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 02 Jun 2025 02 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 Jun 2025 02 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K LINERIXIBAT FILE ACCEPTED FOR REVIEW BY US FDA 02 Jun 2025 02 Jun 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 02 Jun 2025 02 Jun 2025 001-15170
SD Open SD document View SEC filing for SD SPECIALIZED DISCLOSURE REPORT 30 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 30 May 2025 30 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 29 May 2025 29 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK STOPS PHASE 3 TRIAL ON CUTIS FOR EFFICACY 28 May 2025 28 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 28 May 2025 28 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 27 May 2025 27 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K POSITIVE CHMP OPINION ON BLENREP IN EU 23 May 2025 23 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K FDA APPROVES NUCALA COPD INDICATION 23 May 2025 23 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 23 May 2025 23 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 22 May 2025 22 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 21 May 2025 21 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 20 May 2025 20 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 20 May 2025 20 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K BLENREP FOR 2L+ MULTIPLE MYELOMA APPROVED IN JAPAN 19 May 2025 19 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 19 May 2025 19 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 16 May 2025 16 May 2025 001-15170
25-NSE Open 25-NSE document View SEC filing for 25-NSE 15 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 15 May 2025 15 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK TO ACQUIRE EFIMOSFERMIN 14 May 2025 14 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 14 May 2025 14 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 May 2025 13 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K UPDATE ON BELRESTOTUG DEVELOPMENT PROGRAMME 13 May 2025 13 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 13 May 2025 13 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING INTERIM REVIEW 12 May 2025 12 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 12 May 2025 12 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 09 May 2025 09 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 08 May 2025 08 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 08 May 2025 08 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K LINERIXIBAT GLISTEN PIII TRIAL DATA AT EASL 08 May 2025 08 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 08 May 2025 08 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K RESULT OF AGM 07 May 2025 07 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 07 May 2025 07 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 06 May 2025 06 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 02 May 2025 02 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 01 May 2025 01 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 May 2025 01 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K NUCALA MATINEE DATA IN COPD PUBLISHED IN NEJM 01 May 2025 01 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 01 May 2025 01 May 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 30 Apr 2025 30 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K 1ST QUARTER RESULTS 30 Apr 2025 30 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 29 Apr 2025 29 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 28 Apr 2025 28 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 25 Apr 2025 25 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 24 Apr 2025 24 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 23 Apr 2025 23 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 22 Apr 2025 22 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K BLENREP LICENSED BY UK MHRA 17 Apr 2025 17 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 17 Apr 2025 17 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K AREXVY NOW ACIP RECOMMENDED FOR 50-59 AT RIS 17 Apr 2025 17 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK 5-IN-1 MENINGITIS VACCINE RECOMMENDED IN US 17 Apr 2025 17 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 17 Apr 2025 17 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 16 Apr 2025 16 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 15 Apr 2025 15 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 15 Apr 2025 15 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 14 Apr 2025 14 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 14 Apr 2025 14 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 11 Apr 2025 11 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 11 Apr 2025 11 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 10 Apr 2025 10 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 09 Apr 2025 09 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 08 Apr 2025 08 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 07 Apr 2025 07 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 04 Apr 2025 04 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 03 Apr 2025 03 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 02 Apr 2025 02 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Apr 2025 01 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 01 Apr 2025 01 Apr 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 31 Mar 2025 31 Mar 2025 001-15170
SCHEDULE 13D/A Open SCHEDULE 13D/A document View SEC filing for SCHEDULE 13D/A 28 Mar 2025
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 28 Mar 2025 28 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 28 Mar 2025 28 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 27 Mar 2025 27 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 26 Mar 2025 26 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK UUTI TREATMENT APPROVED BY US FDA 25 Mar 2025 25 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 25 Mar 2025 25 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K NOTICE OF AGM 24 Mar 2025 24 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K EMA FILING ACCEPTANCE FOR NUCALA COPD 24 Mar 2025 24 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 24 Mar 2025 24 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 21 Mar 2025 21 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 21 Mar 2025 21 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 20 Mar 2025 20 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 19 Mar 2025 19 Mar 2025 001-15170
CERT Open CERT document View SEC filing for CERT NYSE CERTIFICATION 18 Mar 2025 001-15170
CERT Open CERT document View SEC filing for CERT NYSE CERTIFICATION 18 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 18 Mar 2025 18 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 17 Mar 2025 17 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 14 Mar 2025 14 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 14 Mar 2025 14 Mar 2025 001-15170
8-A12B Open 8-A12B document View SEC filing for 8-A12B 8-A12B 13 Mar 2025 001-15170
8-A12B Open 8-A12B document View SEC filing for 8-A12B 8-A12B 13 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K 6-K 13 Mar 2025 13 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 13 Mar 2025 13 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 12 Mar 2025 12 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 11 Mar 2025 11 Mar 2025 001-15170
424B2 Open 424B2 document | Open XBRL data View SEC filing for 424B2 424B2 10 Mar 2025 333-278205
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 10 Mar 2025 10 Mar 2025 001-15170
SCHEDULE 13G/A Open SCHEDULE 13G/A document View SEC filing for SCHEDULE 13G/A 07 Mar 2025 005-84251
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 07 Mar 2025 07 Mar 2025 001-15170
FWP Open FWP document View SEC filing for FWP FWP 07 Mar 2025 333-278205
424B2 Open 424B2 document View SEC filing for 424B2 424B2 06 Mar 2025 333-278205
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 06 Mar 2025 06 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 05 Mar 2025 05 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 04 Mar 2025 04 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK PLC 2024 ANNUAL REPORT ON FORM 20-F 03 Mar 2025 03 Mar 2025 001-15170
IRANNOTICE Open IRANNOTICE document View SEC filing for IRANNOTICE IRANNOTICE 03 Mar 2025 001-15170
20-F Open 20-F document | Open XBRL data View SEC filing for 20-F 20-F 03 Mar 2025 31 Dec 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 03 Mar 2025 03 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K US FDA ACCEPT 2 DEPEMOKIMAB INDICATION SUBMISSIONS 03 Mar 2025 03 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K ANCHOR RESULTS PRESENTED AT 2025 AAAAI 03 Mar 2025 03 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 03 Mar 2025 03 Mar 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 28 Feb 2025 28 Feb 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 27 Feb 2025 27 Feb 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK PUBLISHES ANNUAL REPORT 2024 27 Feb 2025 27 Feb 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 26 Feb 2025 26 Feb 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 26 Feb 2025 26 Feb 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSACTION IN OWN SHARES 25 Feb 2025 25 Feb 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK COMPLETES ACQUISITION OF IDRX, INC. 24 Feb 2025 24 Feb 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK PLC COMMENCES SHARE BUYBACK PROGRAMME 24 Feb 2025 24 Feb 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTORATE CHANGE 21 Feb 2025 21 Feb 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 21 Feb 2025 21 Feb 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 21 Feb 2025 21 Feb 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 21 Feb 2025 21 Feb 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 21 Feb 2025 21 Feb 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 21 Feb 2025 21 Feb 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 21 Feb 2025 21 Feb 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K NUCALA COPD SUBMISSION ACCEPTED IN CHINA 20 Feb 2025 20 Feb 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK 5-IN-1 MENINGITIS VACCINE APPROVED BY US FDA 18 Feb 2025 18 Feb 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Feb 2025 13 Feb 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 11 Feb 2025 11 Feb 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K FINAL RESULTS 05 Feb 2025 05 Feb 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 03 Feb 2025 03 Feb 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DEPEMOKIMAB DUAL FILING IN CHINA AND JAPAN 28 Jan 2025 28 Jan 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K EMA ACCEPTS TWO SUBMISSIONS FOR DEPEMOKIMAB 28 Jan 2025 28 Jan 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K EMA ACCEPT REVIEW SHINGRIX SYRINGE PRESENTATION 27 Jan 2025 27 Jan 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K JEMPERLI EXPANDED APPROVAL IN THE EU 21 Jan 2025 21 Jan 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 16 Jan 2025 16 Jan 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 15 Jan 2025 15 Jan 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 14 Jan 2025 14 Jan 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Jan 2025 13 Jan 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK ENTERS AGREEMENT TO ACQUIRE IDRX, INC. 13 Jan 2025 13 Jan 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K SHINGRIX FULLY LIQUID ACCEPTED FOR US FDA REVIEW 10 Jan 2025 10 Jan 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK ADC GETS FDA BREAKTHROUGH THERAPY DESIGNATION 07 Jan 2025 07 Jan 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK'S NUCALA APPROVED IN CHINA FOR USE IN CRSWNP 03 Jan 2025 03 Jan 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 Jan 2025 02 Jan 2025 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 23 Dec 2024 23 Dec 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING APPLICATION 20 Dec 2024 20 Dec 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K HEADLINE RESULTS FROM PHASE III FIRST TRIAL 20 Dec 2024 20 Dec 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K JEMPERLI RECEIVES US FDA BREAKTHROUGH DESIGNATION 16 Dec 2024 16 Dec 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K EMA GRANTS PRIME DESIGNATION FOR GSK 227 16 Dec 2024 16 Dec 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K JEMPERLI RECEIVES POSITIVE CHMP OPINION 16 Dec 2024 16 Dec 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Dec 2024 12 Dec 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K OVERALL SURVIVAL DATA PRESENTED FOR BLENREP 09 Dec 2024 09 Dec 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K BLENREP COMBINATION CHINA FILING ACCEPTANCE 09 Dec 2024 09 Dec 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K NUCALA COPD SUBMISSION ACCEPTED BY US FDA 09 Dec 2024 09 Dec 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K ZHIFEI CHINA COLLABORATION REVISED AND EXTENDED 05 Dec 2024 05 Dec 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 02 Dec 2024 02 Dec 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 Dec 2024 02 Dec 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK LIQUID MENINGITIS VACCINE AUTHORISED IN EU 27 Nov 2024 27 Nov 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K BLENREP COMBINATIONS ACCEPTED FOR US FDA REVIEW 25 Nov 2024 25 Nov 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K JAPAN APPROVES FIRST RSV VACCINE FOR ADULTS 50-59 22 Nov 2024 22 Nov 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 19 Nov 2024 19 Nov 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K GLISTEN TRIAL OF LINERIXIBAT MEETS ENDPOINT 19 Nov 2024 19 Nov 2024 001-15170
SC 13D/A Open SC 13D/A document View SEC filing for SC 13D/A AMENDMENT TO THE SCHEDULE 13D 15 Nov 2024
6-K Open 6-K document View SEC filing for 6-K GSK ANNOUNCES OVERALL SURVIVAL RESULTS FOR BLENREP 14 Nov 2024 14 Nov 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING INTERIM REVIEW 13 Nov 2024 13 Nov 2024 001-15170
SC 13G/A Open SC 13G/A document View SEC filing for SC 13G/A AMENDMENT TO FORM SC 13G 12 Nov 2024 005-84251
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Nov 2024 12 Nov 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK PUBLISHES PROVISIONAL 2025 DIVIDEND DATES 12 Nov 2024 12 Nov 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Nov 2024 01 Nov 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 30 Oct 2024 30 Oct 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K 3RD QUARTER RESULTS 30 Oct 2024 30 Oct 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K NEW POSITIVE AREXVY DATA IN YOUNGER ADULTS AT RISK 24 Oct 2024 24 Oct 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 17 Oct 2024 17 Oct 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 16 Oct 2024 16 Oct 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K FDA ACCEPTS NEW DRUG APPLICATION FOR GEPOTIDACIN 16 Oct 2024 16 Oct 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 15 Oct 2024 15 Oct 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K POSITIVE RESULTS OF ANCHOR TRIALS OF DEPEMOKIMAB 15 Oct 2024 15 Oct 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 11 Oct 2024 11 Oct 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 10 Oct 2024 10 Oct 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K ZANTAC (RANITIDINE) LITIGATION SETTLEMENTS 09 Oct 2024 09 Oct 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K POSITIVE EFFICACY DATA OF AREXVY OVER 3 SEASONS 08 Oct 2024 08 Oct 2024 001-15170
4 Open 4 document View SEC filing for 4 WVE - CHANGE IN BENEFICIAL OWNERSHIP 01 Oct 2024 27 Sep 2024 001-37627
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Oct 2024 01 Oct 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 24 Sep 2024 24 Sep 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K POSITIVE EU OPINION FOR GSK LIQUID MENVEO VACCINE 24 Sep 2024 24 Sep 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION 18 Sep 2024 18 Sep 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K JAPAN FILING ACCEPTANCE: BLENREP MULTIPLE MYELOMA 17 Sep 2024 17 Sep 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K CHINA BREAKTHROUGH THERAPY DESIGNATION FOR BLENREP 13 Sep 2024 13 Sep 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Sep 2024 12 Sep 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K POSITIVE MRNA FLU VACCINE PHASE II HEADLINE DATA 12 Sep 2024 12 Sep 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION 11 Sep 2024 11 Sep 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K CHANGE OF REGISTERED OFFICE 11 Sep 2024 11 Sep 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K UPDATE ON PHASE I/II THERAPEUTIC HSV VACCINE TRIAL 11 Sep 2024 11 Sep 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DEPEMOKIMAB LATE-BREAKING DATA PRESENTED AT ERS 09 Sep 2024 09 Sep 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 06 Sep 2024 06 Sep 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K POSITIVE PHASE III RESULTS FOR NUCALA IN COPD 06 Sep 2024 06 Sep 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 03 Sep 2024 03 Sep 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K EMA APPROVAL ON AREXVY FOR 50-59 AT RISK 29 Aug 2024 29 Aug 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K NUCALA APPROVED IN JAPAN FOR USE IN CRSWNP 28 Aug 2024 28 Aug 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K SENKU DESIGNATION FOR BEPIROVIRSEN IN JAPAN 28 Aug 2024 28 Aug 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION 28 Aug 2024 28 Aug 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 21 Aug 2024 21 Aug 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 20 Aug 2024 20 Aug 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K B7-H3 ADC US FDA BREAKTHROUGH THERAPY DESIGNATION 20 Aug 2024 20 Aug 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION 16 Aug 2024 16 Aug 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Aug 2024 12 Aug 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION 06 Aug 2024 06 Aug 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K FDA EXPANDS JEMPERLI APPROVAL 02 Aug 2024 02 Aug 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Aug 2024 01 Aug 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K 2ND QUARTER RESULTS 31 Jul 2024 31 Jul 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION 29 Jul 2024 29 Jul 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K CHMP POSITIVE OPINION ON AREXVY FOR 50-59 AT RISK 29 Jul 2024 29 Jul 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K BLENREP EMA FILING ACCEPTANCE 19 Jul 2024 19 Jul 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 18 Jul 2024 18 Jul 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 16 Jul 2024 16 Jul 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 15 Jul 2024 15 Jul 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Jul 2024 12 Jul 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK AND CUREVAC COLLABORATION RESTRUCTURED 03 Jul 2024 03 Jul 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Jul 2024 01 Jul 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION 28 Jun 2024 28 Jun 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K EMA VALIDATES JEMPERLI MARKETING AUTHORISATION 24 Jun 2024 24 Jun 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K OMJJARA APPROVED IN JAPAN FOR MYELOFIBROSIS 24 Jun 2024 24 Jun 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 21 Jun 2024 21 Jun 2024 001-15170
11-K Open 11-K document View SEC filing for 11-K ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE 18 Jun 2024 31 Dec 2023 001-15170
11-K Open 11-K document View SEC filing for 11-K ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE 18 Jun 2024 31 Dec 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Jun 2024 12 Jun 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION 11 Jun 2024 11 Jun 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION 10 Jun 2024 10 Jun 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K FDA APPROVES AREXVY FOR ADULTS 50-59 AT RISK 10 Jun 2024 10 Jun 2024 001-15170
25-NSE Open 25-NSE document View SEC filing for 25-NSE 03 Jun 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 03 Jun 2024 03 Jun 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K UNPRECEDENTED RESULTS IN JEMPERLI TRIAL CONTINUE 03 Jun 2024 03 Jun 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K ASCO POSITIVE BLENREP DREAMM-8 TRIAL RESULTS 03 Jun 2024 03 Jun 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION 03 Jun 2024 03 Jun 2024 001-15170
SD Open SD document View SEC filing for SD SPECIALIZED DISCLOSURE REPORT 31 May 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION 24 May 2024 24 May 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K POSITIVE PHASE III ASTHMA RESULTS FOR DEPEMOKIMAB 21 May 2024 21 May 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 20 May 2024 20 May 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K CURRENT REPORT 17 May 2024 17 May 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK COMPLETES SALE OF SHARES IN HALEON PLC 17 May 2024 17 May 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 14 May 2024 14 May 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING INTERIM REVIEW 13 May 2024 13 May 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K RESULT OF AGM 08 May 2024 08 May 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K BOARD COMMITTEE CHANGE 08 May 2024 08 May 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 03 May 2024 03 May 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K 1ST QUARTER RESULTS 01 May 2024 01 May 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 May 2024 01 May 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K US FDA ACCEPTS NEW INDICATION FILING FOR JEMPERLI 24 Apr 2024 24 Apr 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 19 Apr 2024 19 Apr 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 17 Apr 2024 17 Apr 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K RESULTS FROM LONG-TERM DATA RELATING TO SHINGRIX 17 Apr 2024 17 Apr 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK ANNOUNCES ADDITIONAL EAGLE-1 RESULTS 17 Apr 2024 17 Apr 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K AMENDMENT - DIRECTOR/PDMR SHAREHOLDING 16 Apr 2024 16 Apr 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K FDA ACCEPTS GSK MENINGITIS VACCINE CANDIDATE FILE 16 Apr 2024 16 Apr 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 15 Apr 2024 15 Apr 2024 001-15170
6-K/A Open 6-K/A document View SEC filing for 6-K/A REPLACEMENT - TOTAL VOTING RIGHTS 04 Apr 2024 04 Apr 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 Apr 2024 02 Apr 2024 001-15170
SC 13D/A Open SC 13D/A document View SEC filing for SC 13D/A AMENDMENT TO FORM SC 13D 28 Mar 2024
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 26 Mar 2024 26 Mar 2024 001-15170
F-3ASR Open F-3ASR document View SEC filing for F-3ASR F-3ASR 25 Mar 2024 333-278205
6-K Open 6-K document View SEC filing for 6-K NOTICE OF AGM 25 Mar 2024 25 Mar 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSFER OF TREASURY SHARES 22 Mar 2024 22 Mar 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 22 Mar 2024 22 Mar 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K NEW PHASE III JEMPERLI DATA IN ENDOMETRIAL CANCER 18 Mar 2024 18 Mar 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Mar 2024 13 Mar 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K BOARD COMMITTEE CHANGE 08 Mar 2024 08 Mar 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK ANNOUNCES POSITIVE BLENREP DREAMM-8 RESULTS 07 Mar 2024 07 Mar 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K VIIV LAI VS ORAL SOC DATA IN ADHERENCE-CHALLENGED 06 Mar 2024 06 Mar 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK ANNUAL REPORT 2023 ON FORM 20 F 05 Mar 2024 05 Mar 2024 001-15170
IRANNOTICE Open IRANNOTICE document View SEC filing for IRANNOTICE IRANNOTICE 05 Mar 2024 001-15170
20-F Open 20-F document | Open XBRL data View SEC filing for 20-F 20-F 05 Mar 2024 31 Dec 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K NEW VIIV LA FORMULATION POTENTIAL 4-MONTH DOSING 05 Mar 2024 05 Mar 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Mar 2024 01 Mar 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK PUBLISHES ANNUAL REPORT 2023 01 Mar 2024 01 Mar 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTORATE CHANGE 29 Feb 2024 29 Feb 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION 29 Feb 2024 29 Feb 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 26 Feb 2024 26 Feb 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK ANNOUNCES POSITIVE EAGLE-1 HEADLINE RESULTS 26 Feb 2024 26 Feb 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 22 Feb 2024 22 Feb 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K VIIV LAI SUPERIOR TO ORALS IN ADHERENCE-CHALLENGED 21 Feb 2024 21 Feb 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 20 Feb 2024 20 Feb 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 15 Feb 2024 15 Feb 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK COMPLETES ACQUISITION OF AIOLOS BIO 15 Feb 2024 15 Feb 2024 001-15170
SC 13G/A Open SC 13G/A document View SEC filing for SC 13G/A SC 13G/A 13 Feb 2024 005-84251
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Feb 2024 13 Feb 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Feb 2024 13 Feb 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Feb 2024 13 Feb 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Feb 2024 12 Feb 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Feb 2024 12 Feb 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Feb 2024 12 Feb 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K US FDA FAST TRACK DESIGNATION FOR BEPIROVIRSEN 12 Feb 2024 12 Feb 2024 001-15170
SC 13D/A Open SC 13D/A document View SEC filing for SC 13D/A AMENDMENT TO SC 13D 09 Feb 2024
SC 13G/A Open SC 13G/A document View SEC filing for SC 13G/A AMENDMENT TO FORM SC 13G 06 Feb 2024
SC 13G/A Open SC 13G/A document View SEC filing for SC 13G/A AMENDMENT TO FORM SC 13G 06 Feb 2024
6-K Open 6-K document View SEC filing for 6-K FDA ACCEPTS AREXVY FILING FOR ADULTS 50-59 AT RISK 06 Feb 2024 06 Feb 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K SHINGRIX 18+ AT RISK CHINA FILING REVIEW ACCEPTED 06 Feb 2024 06 Feb 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK PRESENTS POSITIVE DREAMM-7 PHASE III DATA 06 Feb 2024 06 Feb 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 01 Feb 2024 01 Feb 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Feb 2024 01 Feb 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION 01 Feb 2024 01 Feb 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K FINAL RESULTS 31 Jan 2024 31 Jan 2024 001-15170
4 Open 4 document View SEC filing for 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP 30 Jan 2024 07 Dec 2023 001-37627
6-K Open 6-K document View SEC filing for 6-K EMA ACCEPTS AREXVY FILING FOR ADULTS 50-59 AT RISK 29 Jan 2024 29 Jan 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K EUROPEAN COMMISSION AUTHORISES OMJJARA IN THE EU 29 Jan 2024 29 Jan 2024 001-15170
SC 13D/A Open SC 13D/A document View SEC filing for SC 13D/A AMENDMENT TO FORM SC 13D 19 Jan 2024
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 19 Jan 2024 19 Jan 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 17 Jan 2024 17 Jan 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K CURRENT REPORT 17 Jan 2024 16 Jan 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK COMPLETES SALE OF SHARES IN HALEON PLC 17 Jan 2024 17 Jan 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 16 Jan 2024 16 Jan 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K NUCALA APPROVED IN CHINA FOR USE IN SEVERE ASTHMA 10 Jan 2024 10 Jan 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK ENTERS AGREEMENT TO ACQUIRE AIOLOS BIO 09 Jan 2024 09 Jan 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 Jan 2024 02 Jan 2024 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 21 Dec 2023 21 Dec 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K JEMPERLI PLUS ZEJULA TRIAL MEETS ENDPOINT 18 Dec 2023 18 Dec 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Dec 2023 13 Dec 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K JAPAN ACCEPTS AREXVY FILING FOR AT RISK ADULTS 12 Dec 2023 11 Dec 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K JEMPERLI PLUS CHEMOTHERAPY EU AUTHORISATION 11 Dec 2023 11 Dec 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK PUBLISHES PROVISIONAL 2024 DIVIDEND DATES 04 Dec 2023 04 Dec 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Dec 2023 01 Dec 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING APPLICATION 30 Nov 2023 30 Nov 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K HOLDING(S) IN COMPANY 29 Nov 2023 29 Nov 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK ANNOUNCES POSITIVE DREAMM-7 HEADLINE RESULTS 27 Nov 2023 27 Nov 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 21 Nov 2023 21 Nov 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING INTERIM REVIEW 15 Nov 2023 15 Nov 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Nov 2023 13 Nov 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK RECEIVES POSITIVE CHMP OPINION FOR MOMELOTINIB 13 Nov 2023 13 Nov 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Nov 2023 01 Nov 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K 3RD QUARTER RESULTS 01 Nov 2023 01 Nov 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K JEMPERLI TRIAL MEETS OVERALL SURVIVAL ENDPOINT 30 Oct 2023 30 Oct 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K NMPA APPROVES VOCABRIA+REKAMBYS IN CHINA 26 Oct 2023 26 Oct 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 25 Oct 2023 25 Oct 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K NEW DATA FOR AREXVY, GSK'S RSV VACCINE 25 Oct 2023 25 Oct 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 20 Oct 2023 20 Oct 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 18 Oct 2023 18 Oct 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 17 Oct 2023 17 Oct 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K JEMPERLI PLUS CHEMOTHERAPY POSITIVE CHMP OPINION 16 Oct 2023 16 Oct 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Oct 2023 13 Oct 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Oct 2023 12 Oct 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K ZANTAC (RANITIDINE) LITIGATION 11 Oct 2023 11 Oct 2023 001-15170
SC 13D/A Open SC 13D/A document View SEC filing for SC 13D/A AMENDMENT TO FORM SC 13D 10 Oct 2023
6-K Open 6-K document View SEC filing for 6-K GSK AND ZHIFEI ANNOUNCE VACCINE PARTNERSHIP 10 Oct 2023 10 Oct 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K CURRENT REPORT 06 Oct 2023 06 Oct 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK COMPLETES SALE OF SHARES IN HALEON PLC 06 Oct 2023 06 Oct 2023 001-15170
25-NSE Open 25-NSE document View SEC filing for 25-NSE 02 Oct 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 Oct 2023 02 Oct 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTORATE CHANGE 27 Sep 2023 27 Sep 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK RSV VACCINE FOR OLDER ADULTS APPROVED IN JAPAN 25 Sep 2023 25 Sep 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 21 Sep 2023 21 Aug 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K APRETUDE FOR PREP RECEIVES EMA APPROVAL 19 Sep 2023 19 Sep 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K FDA APPROVES OJJAARA (MOMELOTINIB) 18 Sep 2023 18 Sep 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Sep 2023 13 Sep 2023 001-15170
SC 13D/A Open SC 13D/A document View SEC filing for SC 13D/A AMENDMENT TO FORM SC 13D 11 Sep 2023
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 11 Sep 2023 11 Sep 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K MOMELOTINIB FILING ACCEPTED IN JAPAN 11 Sep 2023 11 Sep 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 06 Sep 2023 06 Sep 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Sep 2023 01 Sep 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK'S NUCALA CRSWNP SUBMISSION ACCEPTED IN JAPAN 01 Sep 2023 01 Sep 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K HOLDING(S) IN COMPANY 31 Aug 2023 31 Aug 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K HOLDING(S) IN COMPANY 31 Aug 2023 31 Aug 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 25 Aug 2023 25 Aug 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 23 Aug 2023 23 Aug 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K SHINGRIX DATA DEMONSTRATE 100% EFFICACY IN CHINA 23 Aug 2023 23 Aug 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 22 Aug 2023 22 Aug 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 10 Aug 2023 10 Aug 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 09 Aug 2023 09 Aug 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Aug 2023 01 Aug 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K FDA APPROVES NEW USE FOR JEMPERLI PLUS CHEMO 31 Jul 2023 31 Jul 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 31 Jul 2023 31 Jul 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 28 Jul 2023 28 Jul 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K 2ND QUARTER RESULTS 26 Jul 2023 26 Jul 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K CABOTEGRAVIR LA FOR PREP RECEIVES POSITIVE CHMP 24 Jul 2023 24 Jul 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 20 Jul 2023 20 Jul 2023 001-15170
SC 13D/A Open SC 13D/A document View SEC filing for SC 13D/A AMENDMENT TO FORM SC 13D 20 Jul 2023
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 17 Jul 2023 17 Jul 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Jul 2023 13 Jul 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 03 Jul 2023 03 Jul 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK COMPLETES ACQUISITION OF BELLUS HEALTH 28 Jun 2023 28 Jun 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K FDA FAST TRACK FOR GONORRHOEA VACCINE CANDIDATE 27 Jun 2023 27 Jun 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK DAPRODUSTAT GAINS POSITIVE EMA CHMP OPINION 26 Jun 2023 26 Jun 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K SHINGRIX APPROVED IN JAPAN FOR ADULTS 18 AND OVER 26 Jun 2023 26 Jun 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 23 Jun 2023 23 Jun 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 23 Jun 2023 23 Jun 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 23 Jun 2023 23 Jun 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION 23 Jun 2023 23 Jun 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K GSKS AREXVY RECOMMENDED BY ACIP 22 Jun 2023 22 Jun 2023 001-15170
11-K Open 11-K document View SEC filing for 11-K ANNUAL REPORT 21 Jun 2023 31 Dec 2022 001-15170
11-K Open 11-K document View SEC filing for 11-K ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE 21 Jun 2023 31 Dec 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K SEASON TWO DATA FOR GSK AREXVY RSV OA VACCINE 21 Jun 2023 21 Jun 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K EXTENSION OF FDA REVIEW PERIOD FOR MOMELOTINIB 16 Jun 2023 16 Jun 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Jun 2023 12 Jun 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K EU AUTHORISATION OF GSKS RSV VACCINE AREXVY 07 Jun 2023 07 Jun 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK RECEIVES US FDA FILE ACCEPTANCE FOR JEMPERLI 06 Jun 2023 06 Jun 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Jun 2023 01 Jun 2023 001-15170
SD Open SD document View SEC filing for SD SPECIALIZED DISCLOSURE 30 May 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 22 May 2023 22 May 2023 001-15170
SC 13D/A Open SC 13D/A document View SEC filing for SC 13D/A AMENDMENT TO FORM SC 13D 16 May 2023
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 15 May 2023 15 May 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING INTERIM REVIEW 15 May 2023 15 May 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 May 2023 12 May 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K MENABCWY VACCINE PRELIMINARY PHASE III RESULTS 12 May 2023 12 May 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K STATEMENT: ZANTAC LITIGATION UPDATE BC CANADA 12 May 2023 12 May 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK COMPLETES SALE OF SHARES IN HALEON PLC 12 May 2023 12 May 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K CURRENT REPORT OF FOREIGN ISSUER 12 May 2023 11 May 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 09 May 2023 09 May 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 04 May 2023 04 May 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K RESULT OF AGM 03 May 2023 03 May 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K US FDA APPROVES GSKS RSV VACCINE FOR OLDER ADULTS 03 May 2023 03 May 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 May 2023 02 May 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 28 Apr 2023 28 Apr 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK RSV OA VACCINE GAINS POSITIVE EMA CHMP OPINION 27 Apr 2023 27 Apr 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K 1ST QUARTER RESULTS 26 Apr 2023 26 Apr 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K EMA VALIDATES JEMPERLI FILING FOR NEW INDICATION 25 Apr 2023 25 Apr 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 20 Apr 2023 20 Apr 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 19 Apr 2023 19 Apr 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK REACHES AGREEMENT TO ACQUIRE BELLUS HEALTH INC 18 Apr 2023 18 Apr 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 17 Apr 2023 17 Apr 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K GEPOTIDACIN POSITIVE PHASE III DATA 17 Apr 2023 17 Apr 2023 001-15170
20-F/A Open 20-F/A document | Open XBRL data View SEC filing for 20-F/A 20-F/A 17 Apr 2023 31 Dec 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 03 Apr 2023 03 Apr 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K POSITIVE PHASE III RUBY RESULTS FOR JEMPERLI 28 Mar 2023 28 Mar 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K PUBLICATION OF 2023 AGM NOTICE 27 Mar 2023 27 Mar 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION 24 Mar 2023 24 Mar 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 21 Mar 2023 21 Mar 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 20 Mar 2023 20 Mar 2023 001-15170
EFFECT Open EFFECT document View SEC filing for EFFECT 15 Mar 2023 333-254756
6-K Open 6-K document View SEC filing for 6-K POSITIVE PHASE III RESULTS FOR MENABCWY VACCINE 14 Mar 2023 14 Mar 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K NUCALA NDA ACCEPTED FOR REVIEW IN CHINA 14 Mar 2023 14 Mar 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Mar 2023 13 Mar 2023 001-15170
POS AM Open POS AM document View SEC filing for POS AM POS AM 10 Mar 2023 333-254756
6-K Open 6-K document View SEC filing for 6-K GSK ANNUAL REPORT 2022 ON FORM 20-F 10 Mar 2023 10 Mar 2023 001-15170
IRANNOTICE Open IRANNOTICE document View SEC filing for IRANNOTICE IRANNOTICE 10 Mar 2023 001-15170
20-F Open 20-F document | Open XBRL data View SEC filing for 20-F 20-F 10 Mar 2023 31 Dec 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK PUBLISHES ANNUAL REPORT 2022 10 Mar 2023 10 Mar 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K FDA AD COM VOTES TO SUPPORT GSK RSV OA VACCINE 02 Mar 2023 02 Mar 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Mar 2023 01 Mar 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 27 Feb 2023 27 Feb 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 23 Feb 2023 23 Feb 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K VIIV HEALTHCARE ANNOUNCES CABENUVA POSITIVE DATA 23 Feb 2023 23 Feb 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 22 Feb 2023 22 Feb 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K NEJM PUBLISHES GSK RSV OA VACCINE CANDIDATE TRIAL 16 Feb 2023 16 Feb 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 15 Feb 2023 15 Feb 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 15 Feb 2023 15 Feb 2023 001-15170
SC 13G/A Open SC 13G/A document View SEC filing for SC 13G/A SC 13G/A 14 Feb 2023 005-84251
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 14 Feb 2023 14 Feb 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 14 Feb 2023 14 Feb 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 14 Feb 2023 14 Feb 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 14 Feb 2023 14 Feb 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 10 Feb 2023 10 Feb 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K JEMPERLI FULL FDA APPROVAL FOLLOWING GARNET TRIAL 10 Feb 2023 10 Feb 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K JEMPERLI FDA ODAC POSITIVE OUTCOME 10 Feb 2023 10 Feb 2023 001-15170
SC 13G Open SC 13G document View SEC filing for SC 13G SCHEDULE 13G 06 Feb 2023
6-K Open 6-K document View SEC filing for 6-K DAPRODUSTAT APPROVED BY US FDA FOR ANAEMIA OF CKD 02 Feb 2023 02 Feb 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 01 Feb 2023 01 Feb 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Feb 2023 01 Feb 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K BENLYSTA GRANTED ORPHAN DRUG DESIGNATION BY US FDA 01 Feb 2023 01 Feb 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K FINAL RESULTS 01 Feb 2023 01 Feb 2023 001-15170
SC 13G Open SC 13G document View SEC filing for SC 13G SCHEDULE 13G 30 Jan 2023
3 Open 3 document View SEC filing for 3 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP 30 Jan 2023 23 Jan 2023 001-37627
SC 13D/A Open SC 13D/A document View SEC filing for SC 13D/A AMENDMENT TO FORM SC 13D 20 Jan 2023
SC 13D/A Open SC 13D/A document View SEC filing for SC 13D/A SCHEDULE 13D/A 20 Jan 2023
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 18 Jan 2023 18 Jan 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 17 Jan 2023 17 Jan 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 17 Jan 2023 17 Jan 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Jan 2023 13 Jan 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Jan 2023 12 Jan 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 03 Jan 2023 03 Jan 2023 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 22 Dec 2022 22 Dec 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 21 Dec 2022 21 Dec 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 21 Dec 2022 21 Dec 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K BOARD AND COMMITTEE CHANGES 15 Dec 2022 15 Dec 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Dec 2022 13 Dec 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION 07 Dec 2022 07 Dec 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K TRANSFER OF TREASURY SHARES 05 Dec 2022 05 Dec 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 02 Dec 2022 02 Dec 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K JEMPERLI POSITIVE TRIAL IN ENDOMETRIAL CANCER 02 Dec 2022 02 Dec 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K EMA FILE ACCEPTED FOR MOMELOTINIB 02 Dec 2022 02 Dec 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Dec 2022 01 Dec 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK PUBLISHES PROVISIONAL 2023 DIVIDEND DATES 25 Nov 2022 25 Nov 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K BLENREP US UPDATE 22 Nov 2022 22 Nov 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 21 Nov 2022 21 Nov 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING INTERIM REVIEW 15 Nov 2022 15 Nov 2022 001-15170
3 Open 3 document View SEC filing for 3 14 Nov 2022 07 Nov 2022 001-38266
SC 13D/A Open SC 13D/A document View SEC filing for SC 13D/A SCHEDULE 13D/A 14 Nov 2022
6-K Open 6-K document View SEC filing for 6-K GSK UPDATE: ZEJULA 2L IN US 14 Nov 2022 14 Nov 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K SANOFI-GSK COVID BOOSTER VACCINE APPROVED BY EU 10 Nov 2022 10 Nov 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 10 Nov 2022 10 Nov 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING APPLICATION 10 Nov 2022 10 Nov 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DREAMM-3 PHASE III TRIAL FOR BLENREP 07 Nov 2022 07 Nov 2022 001-15170
3 Open 3 document View SEC filing for 3 ME - INITIAL STATEMENT OF BENEFICIAL OWNERSHIP 04 Nov 2022 16 Jun 2021 001-39587
SC 13D Open SC 13D document View SEC filing for SC 13D ACQUISITION OF BENEFICIAL OWNERSHIP 04 Nov 2022
6-K Open 6-K document View SEC filing for 6-K IDMC RECOMMENDS GEPOTIDACIN EARLY EFFICACY STOP 03 Nov 2022 03 Nov 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K 3RD QUARTER RESULTS 02 Nov 2022 02 Nov 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK RSV VACCINE: US FDA PRIORITY REVIEW 02 Nov 2022 02 Nov 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Nov 2022 01 Nov 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K EMA ACCEPTS GSK RSV OLDER ADULT VACCINE FOR REVIEW 28 Oct 2022 28 Oct 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K EMA VALIDATES MAA FOR CABOTEGRAVIR LA FOR PREP 28 Oct 2022 28 Oct 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK ANNOUNCES FDA MEETING OUTCOME ON DAPRODUSTAT 27 Oct 2022 27 Oct 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K CONTRAST PHASE III PROGRAMME FOR OTILIMAB UPDATE 27 Oct 2022 27 Oct 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K BOARD COMMITTEE CHANGES 25 Oct 2022 25 Oct 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K RSV OLDER ADULT VACCINE SUBMISSION IN JAPAN 21 Oct 2022 21 Oct 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K MENVEO NEW SINGLE-VIAL APPROVED BY US FDA 17 Oct 2022 17 Oct 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 14 Oct 2022 14 Oct 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Oct 2022 13 Oct 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Oct 2022 13 Oct 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Oct 2022 13 Oct 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K EFFICACY RESULTS FOR GSK'S OLDER ADULT RSV VACCINE 13 Oct 2022 13 Oct 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Oct 2022 12 Oct 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K US FDA APPROVES BOOSTRIX MATERNAL IMMUNISATION 11 Oct 2022 11 Oct 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 07 Oct 2022 07 Oct 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 07 Oct 2022 07 Oct 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 03 Oct 2022 03 Oct 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 30 Sep 2022 30 Sep 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 26 Sep 2022 26 Sep 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK CHIEF FINANCIAL OFFICER SUCCESSION 26 Sep 2022 26 Sep 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K US FDA ODAC REVIEW OF ZEJULA PHASE III NOVA TRIAL 22 Sep 2022 22 Sep 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK AND SPERO THERAPEUTICS LICENCE FOR TEBIPENEM 22 Sep 2022 22 Sep 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 21 Sep 2022 21 Sep 2022 001-15170
4 Open 4 document View SEC filing for 4 20 Sep 2022 16 Sep 2022 001-36033
SC 13D/A Open SC 13D/A document View SEC filing for SC 13D/A AMENDMENT TO FORM SC 13D 20 Sep 2022
25-NSE Open 25-NSE document View SEC filing for 25-NSE 15 Sep 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Sep 2022 13 Sep 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 08 Sep 2022 08 Sep 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK PROVIDES UPDATE ON FDA REVIEW OF DAPRODUSTAT 06 Sep 2022 06 Sep 2022 001-15170
25-NSE Open 25-NSE document View SEC filing for 25-NSE 01 Sep 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Sep 2022 01 Sep 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK BOARD CHANGES 24 Aug 2022 24 Aug 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 22 Aug 2022 22 Aug 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K FDA NEW DRUG APPLICATION FILE ACCEPTANCE FOR MMB 17 Aug 2022 17 Aug 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION UPDATE 17 Aug 2022 17 Aug 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK COMPLETES ACQUISITION OF AFFINIVAX, INC. 16 Aug 2022 16 Aug 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K STATEMENT: ZANTAC (RANITIDINE) LITIGATION 12 Aug 2022 12 Aug 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 11 Aug 2022 11 Aug 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 10 Aug 2022 10 Aug 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K CURRENT REPORT OF FOREIGN ISSUER 03 Aug 2022 03 Aug 2022 001-15170
SC 13D/A Open SC 13D/A document View SEC filing for SC 13D/A AMENDMENT TO FORM SC 13D 03 Aug 2022
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Aug 2022 01 Aug 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 01 Aug 2022 01 Aug 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 29 Jul 2022 29 Jul 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK BOARD CHANGE 29 Jul 2022 29 Jul 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 28 Jul 2022 28 Jul 2022 001-15170
SC 13D Open SC 13D document View SEC filing for SC 13D SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP 27 Jul 2022
6-K Open 6-K document View SEC filing for 6-K 2ND QUARTER RESULTS 27 Jul 2022 27 Jul 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K HOLDING(S) IN COMPANY 22 Jul 2022 22 Jul 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K BOARD AND COMMITTEE CHANGES 22 Jul 2022 22 Jul 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K COMPLETION OF GSK SHARE CONSOLIDATION 18 Jul 2022 18 Jul 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K HALEON DEMERGER COMPLETION AND SHARE CONSOLIDATION 18 Jul 2022 18 Jul 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Jul 2022 12 Jul 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 08 Jul 2022 08 Jul 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 08 Jul 2022 08 Jul 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 08 Jul 2022 08 Jul 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 08 Jul 2022 08 Jul 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 08 Jul 2022 08 Jul 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K RESULT OF GENERAL MEETING 06 Jul 2022 06 Jul 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 06 Jul 2022 06 Jul 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK DISCLOSE DISCONTINUED OPERATIONS FROM Q2 2022 05 Jul 2022 05 Jul 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 05 Jul 2022 05 Jul 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 05 Jul 2022 05 Jul 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Jul 2022 01 Jul 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK COMPLETES ACQUISITION OF SIERRA ONCOLOGY 01 Jul 2022 01 Jul 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 28 Jun 2022 28 Jun 2022 001-15170
11-K Open 11-K document View SEC filing for 11-K ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE 28 Jun 2022 31 Dec 2021 001-15170
11-K Open 11-K document View SEC filing for 11-K ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE 28 Jun 2022 31 Dec 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK FILES SHINGRIX 18+ AT RISK INDICATION IN JAPAN 28 Jun 2022 28 Jun 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 27 Jun 2022 27 Jun 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 24 Jun 2022 24 Jun 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 16 Jun 2022 16 Jun 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K POSITIVE PHASE III DATA FOR GSK'S RSV OA VACCINE 10 Jun 2022 10 Jun 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 09 Jun 2022 09 Jun 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 07 Jun 2022 07 Jun 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K US FDA APPROVAL OF PRIORIX 06 Jun 2022 06 Jun 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K 6-K 01 Jun 2022 01 Jun 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DEMERGER UPDATE: PUBLICATION OF DOCUMENTS 01 Jun 2022 01 Jun 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DEMERGER UPDATE: SUBMISSION OF DOCUMENTS TO FCA 01 Jun 2022 01 Jun 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK TO ACQUIRE AFFINIVAX, INC. 31 May 2022 31 May 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K FURTHER APPOINTMENTS TO DESIGNATE HALEON BOARD 31 May 2022 31 May 2022 001-15170
SD Open SD document View SEC filing for SD SPECIALIZED DISCLOSURE 27 May 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK CERVARIX TWO-DOSE SCHEDULE APPROVED BY NMPA 27 May 2022 26 May 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 25 May 2022 25 May 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 23 May 2022 23 May 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K IAIN MACKAY - EXTERNAL APPOINTMENT 19 May 2022 19 May 2022 001-15170
424B3 Open 424B3 document View SEC filing for 424B3 424B3 17 May 2022 333-264759
424B3 Open 424B3 document View SEC filing for 424B3 424B3 17 May 2022 333-232726
6-K Open 6-K document View SEC filing for 6-K CHANGE OF NAME TO GSK PLC 16 May 2022 16 May 2022 001-15170
SC 13D/A Open SC 13D/A document View SEC filing for SC 13D/A AMENDMENT TO FORM SC 13D 13 May 2022
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 May 2022 13 May 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 May 2022 12 May 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING INTERIM REVIEW 11 May 2022 11 May 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 09 May 2022 09 May 2022 001-15170
25-NSE Open 25-NSE document View SEC filing for 25-NSE 09 May 2022 001-15170
F-6EF Open F-6EF document View SEC filing for F-6EF F-6 06 May 2022 333-264759
6-K Open 6-K document View SEC filing for 6-K RESULT OF AGM 04 May 2022 04 May 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTORATE CHANGE 04 May 2022 04 May 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 03 May 2022 03 May 2022 001-15170
25-NSE Open 25-NSE document View SEC filing for 25-NSE 02 May 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K 1ST QUARTER RESULTS 27 Apr 2022 27 Apr 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 26 Apr 2022 26 Apr 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DAPRODUSTAT APPLICATION ACCEPTED FOR REVIEW BY FDA 19 Apr 2022 19 Apr 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 14 Apr 2022 14 Apr 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 14 Apr 2022 14 Apr 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 14 Apr 2022 14 Apr 2022 001-15170
DFAN14A Open DFAN14A document View SEC filing for DFAN14A DFAN14A 13 Apr 2022
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Apr 2022 13 Apr 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Apr 2022 13 Apr 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK AGREES TO ACQUIRE SIERRA ONCOLOGY FOR $1.9BN 13 Apr 2022 13 Apr 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Apr 2022 12 Apr 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Apr 2022 12 Apr 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Apr 2022 12 Apr 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Apr 2022 12 Apr 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Apr 2022 01 Apr 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK - SEGMENT AND PRODUCT SALES REPORTING CHANGES 01 Apr 2022 01 Apr 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K PUBLICATION OF 2022 AGM NOTICE 28 Mar 2022 28 Mar 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 24 Mar 2022 24 Mar 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K FDA UPDATE: CABENUVA ORAL LEAD-IN NOW OPTIONAL 24 Mar 2022 24 Mar 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 23 Mar 2022 23 Mar 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K ISSUANCE OF NOTES 23 Mar 2022 23 Mar 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 16 Mar 2022 16 Mar 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 15 Mar 2022 15 Mar 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K APPOINTMENTS TO DESIGNATE HALEON BOARD 15 Mar 2022 15 Mar 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 11 Mar 2022 11 Mar 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 09 Mar 2022 09 Mar 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK ANNUAL REPORT 2021 ON FORM 20-F 08 Mar 2022 08 Mar 2022 001-15170
IRANNOTICE Open IRANNOTICE document View SEC filing for IRANNOTICE IRANNOTICE 08 Mar 2022 001-15170
20-F Open 20-F document | Open XBRL data View SEC filing for 20-F 20-F 08 Mar 2022 31 Dec 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK PUBLISHES ANNUAL REPORT 2021 04 Mar 2022 04 Mar 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Mar 2022 01 Mar 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 01 Mar 2022 01 Mar 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 01 Mar 2022 01 Mar 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DAPRODUSTAT APPLICATION ACCEPTED FOR REVIEW BY EMA 01 Mar 2022 01 Mar 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K FOMR 6-K 28 Feb 2022 28 Feb 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K FORM 6-K 28 Feb 2022 28 Feb 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 24 Feb 2022 24 Feb 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K CANADA APPROVAL FOR MEDICAGO GSK COVID-19 VACCINE 24 Feb 2022 24 Feb 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 23 Feb 2022 23 Feb 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 22 Feb 2022 22 Feb 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK CONSUMER HEALTHCARE TO BE CALLED HALEON 22 Feb 2022 22 Feb 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 18 Feb 2022 18 Feb 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK GIVES UPDATE ON RSV MATERNAL VACCINE CANDIDATE 18 Feb 2022 18 Feb 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 17 Feb 2022 17 Feb 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 17 Feb 2022 17 Feb 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 17 Feb 2022 17 Feb 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 17 Feb 2022 17 Feb 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 17 Feb 2022 17 Feb 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 16 Feb 2022 16 Feb 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 14 Feb 2022 14 Feb 2022 001-15170
SC 13G Open SC 13G document View SEC filing for SC 13G SC 13G 14 Feb 2022 005-84251
6-K Open 6-K document View SEC filing for 6-K TRANSFER OF TREASURY SHARES 14 Feb 2022 14 Feb 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 11 Feb 2022 11 Feb 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 11 Feb 2022 11 Feb 2022 001-15170
SC 13G/A Open SC 13G/A document View SEC filing for SC 13G/A AMENDMENT TO SC 13G 10 Feb 2022
SC 13G Open SC 13G document View SEC filing for SC 13G SCHEDULE 13G 10 Feb 2022
SC 13G/A Open SC 13G/A document View SEC filing for SC 13G/A AMENDMENT TO SC 13G 10 Feb 2022
SC 13D/A Open SC 13D/A document View SEC filing for SC 13D/A AMENDMENT TO FORM SC 13D 10 Feb 2022
SC 13G/A Open SC 13G/A document View SEC filing for SC 13G/A AMENDMENT TO FORM SC 13G 10 Feb 2022
6-K Open 6-K document View SEC filing for 6-K BENLYSTA APPROVED IN CHINA FOR LUPUS NEPHRITIS 10 Feb 2022 10 Feb 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K FINAL RESULTS 09 Feb 2022 09 Feb 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 09 Feb 2022 09 Feb 2022 001-15170
SC 13G/A Open SC 13G/A document View SEC filing for SC 13G/A 07 Feb 2022 005-84251
6-K Open 6-K document View SEC filing for 6-K PUBLICATION OF FULL YEAR 2021 RESULTS 07 Feb 2022 07 Feb 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK ANNOUNCES SETTLEMENT BETWEEN VIIV AND GILEAD 02 Feb 2022 02 Feb 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K FDA APPROVES VIIV HEALTHCARE'S SNDA FOR CABENUVA 01 Feb 2022 01 Feb 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Feb 2022 01 Feb 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 26 Jan 2022 26 Jan 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 20 Jan 2022 20 Jan 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 19 Jan 2022 19 Jan 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 19 Jan 2022 19 Jan 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 19 Jan 2022 19 Jan 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K TONY WOOD APPOINTED CSO DESIGNATE, GSK 19 Jan 2022 19 Jan 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 18 Jan 2022 18 Jan 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 18 Jan 2022 18 Jan 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K UPDATE - GSK CONSUMER HEALTHCARE 18 Jan 2022 18 Jan 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 14 Jan 2022 14 Jan 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Jan 2022 13 Jan 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 11 Jan 2022 11 Jan 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K US GOVT BUYS ADDITIONAL 600,000 SOTROVIMAB DOSES 11 Jan 2022 11 Jan 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 04 Jan 2022 04 Jan 2022 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 23 Dec 2021 23 Dec 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 22 Dec 2021 22 Dec 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K VIIV HEALTHCARE ANNOUNCES FDA APPROVAL OF APRETUDE 21 Dec 2021 21 Dec 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K CONSUMER HEALTHCARE CHAIR DESIGNATE APPOINTED 20 Dec 2021 20 Dec 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K XEVUDY APPROVED IN EUROPE TO TREAT COVID-19 17 Dec 2021 17 Dec 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK/SANOFI COVID-19 VACCINE BOOSTER & PH3 UPDATE 15 Dec 2021 15 Dec 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Dec 2021 13 Dec 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Dec 2021 13 Dec 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K MEDICAGO/GSK COVID-19 VACCINE POSITIVE PH3 DATA 07 Dec 2021 07 Dec 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K SOTROVIMAB RETAINS ITS ACTIVITY VS OMICRON VARIANT 07 Dec 2021 07 Dec 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K SOTROVIMAB RETAINS ITS ACTIVITY VS OMICRON VARIANT 02 Dec 2021 02 Dec 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Dec 2021 01 Dec 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 24 Nov 2021 24 Nov 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK PUBLISHES PROVISIONAL 2022 DIVIDEND DATES 24 Nov 2021 24 Nov 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 23 Nov 2021 23 Nov 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K NUCALA APPROVED IN EUROPE FOR MORE INDICATIONS 17 Nov 2021 17 Nov 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING INTERIM REVIEW 15 Nov 2021 15 Nov 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K PHASE III IM ADMINISTRATION DATA FOR SOTROVIMAB 12 Nov 2021 12 Nov 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Nov 2021 12 Nov 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 10 Nov 2021 10 Nov 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK SHARES POSITIVE PHASE III DATA FOR DAPRODUSTAT 05 Nov 2021 05 Nov 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Nov 2021 01 Nov 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K 3RD QUARTER RESULTS 27 Oct 2021 27 Oct 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 27 Oct 2021 27 Oct 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTORATE CHANGE 27 Oct 2021 27 Oct 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 15 Oct 2021 15 Oct 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 14 Oct 2021 14 Oct 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 14 Oct 2021 14 Oct 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Oct 2021 13 Oct 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Oct 2021 12 Oct 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Oct 2021 12 Oct 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Oct 2021 12 Oct 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Oct 2021 12 Oct 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Oct 2021 12 Oct 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Oct 2021 01 Oct 2021 001-15170
SC 13G/A Open SC 13G/A document View SEC filing for SC 13G/A AMENDMENT TO FORM SC 13G 27 Sep 2021
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 24 Sep 2021 24 Sep 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 22 Sep 2021 22 Sep 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR DECLARATION 20 Sep 2021 20 Sep 2021 001-15170
SC 13D/A Open SC 13D/A document View SEC filing for SC 13D/A AMENDMENT TO FORM SC 13D 16 Sep 2021
SC 13D/A Open SC 13D/A document View SEC filing for SC 13D/A AMENDMENT TO FORM SC 13D 16 Sep 2021
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Sep 2021 13 Sep 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 09 Sep 2021 09 Sep 2021 001-15170
UPLOAD Open UPLOAD document View SEC filing for UPLOAD 08 Sep 2021
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 07 Sep 2021 07 Sep 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 03 Sep 2021 03 Sep 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Sep 2021 01 Sep 2021 001-15170
CORRESP Open CORRESP document View SEC filing for CORRESP 31 Aug 2021
6-K Open 6-K document View SEC filing for 6-K SK BIO & GSK START PH3 COVID-19 VACCINE TRIAL 31 Aug 2021 31 Aug 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 25 Aug 2021 25 Aug 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 23 Aug 2021 23 Aug 2021 001-15170
UPLOAD Open UPLOAD document View SEC filing for UPLOAD 18 Aug 2021
6-K/A Open 6-K/A document View SEC filing for 6-K/A DIRECTOR/PDMR SHAREHOLDING - AMENDMENT 13 Aug 2021 13 Aug 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 11 Aug 2021 11 Aug 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 11 Aug 2021 11 Aug 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K BLOCK LISTING APPLICATION 05 Aug 2021 05 Aug 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 02 Aug 2021 02 Aug 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K 2ND QUARTER RESULTS 28 Jul 2021 28 Jul 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 28 Jul 2021 28 Jul 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 26 Jul 2021 26 Jul 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K BOARD COMMITTEE CHANGES 23 Jul 2021 23 Jul 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K CEO DESIGNATE OF NEW CONSUMER HEALTHCARE COMPANY 22 Jul 2021 22 Jul 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK ANNOUNCES DAPRODUSTAT PHASE 3 HEADLINE RESULTS 16 Jul 2021 16 Jul 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 16 Jul 2021 16 Jul 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 15 Jul 2021 15 Jul 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 14 Jul 2021 14 Jul 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 14 Jul 2021 14 Jul 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Jul 2021 13 Jul 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 13 Jul 2021 13 Jul 2021 001-15170
SC 13G Open SC 13G document View SEC filing for SC 13G SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP 12 Jul 2021
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Jul 2021 07 Dec 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 12 Jul 2021 12 Jul 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 09 Jul 2021 09 Jul 2021 001-15170
4 Open 4 document View SEC filing for 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP 06 Jul 2021 02 Jul 2021 001-40545
3 Open 3 document View SEC filing for 3 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP 06 Jul 2021 29 Jun 2021 001-40545
6-K Open 6-K document View SEC filing for 6-K GSK AND ALECTOR COLLABORATION IN IMMUNO-NEUROLOGY 02 Jul 2021 02 Jul 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K ELLIOTT ADVISORS (UK) LETTER TO GSK 02 Jul 2021 02 Jul 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Jul 2021 01 Jul 2021 001-15170
11-K Open 11-K document View SEC filing for 11-K ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE 25 Jun 2021 31 Dec 2020 001-15170
11-K Open 11-K document View SEC filing for 11-K ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE 25 Jun 2021 31 Dec 2020 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 25 Jun 2021 25 Jun 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 24 Jun 2021 24 Jun 2021 001-15170
4 Open 4 document View SEC filing for 4 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES 23 Jun 2021 21 Jun 2021 001-40502
6-K Open 6-K document View SEC filing for 6-K GSK TO DELIVER STEP-CHANGE IN GROWTH & PERFORMANCE 23 Jun 2021 23 Jun 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K VIIV/HALOZYME SIGN EXCLUSIVE LICENSING AGREEMENT 22 Jun 2021 22 Jun 2021 001-15170
3 Open 3 document View SEC filing for 3 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES 17 Jun 2021 16 Jun 2021 001-40502
6-K Open 6-K document View SEC filing for 6-K GSK AND ITEOS ANNOUNCE COLLABORATION FOR EOS-448 14 Jun 2021 14 Jun 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 11 Jun 2021 11 Jun 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 09 Jun 2021 09 Jun 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K TRC CAPITAL LETTER 04 Jun 2021 04 Jun 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K TOTAL VOTING RIGHTS 01 Jun 2021 01 Jun 2021 001-15170
SD Open SD document View SEC filing for SD SD 27 May 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K DIRECTOR/PDMR SHAREHOLDING 27 May 2021 27 May 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K SANOFI AND GSK INITIATE NEW PHASE 3 CLINICAL STUDY 27 May 2021 27 May 2021 001-15170
6-K Open 6-K document View SEC filing for 6-K GSK/VIR SOTROVIMAB FDA EMERGENCY USE AUTHORIZATION 27 May 2021 27 May 2021 001-15170

About this filer

GSK plc files with the SEC under CIK 0001131399. This page aggregates EDGAR filings and related ownership activity.

Industry: Pharmaceutical Preparations.

See reporting owner transactions.

FAQ

What is a CIK?
A Central Index Key (CIK) is a unique identifier assigned by the SEC to each filer.
Why are some filings missing?
New filings appear as the SEC updates EDGAR, and older records can vary by availability.
How often is this page updated?
Updates follow new EDGAR submissions and periodic data refreshes.

Related pages